403 related articles for article (PubMed ID: 11836291)
1. Changes in body composition during androgen deprivation therapy for prostate cancer.
Smith MR; Finkelstein JS; McGovern FJ; Zietman AL; Fallon MA; Schoenfeld DA; Kantoff PW
J Clin Endocrinol Metab; 2002 Feb; 87(2):599-603. PubMed ID: 11836291
[TBL] [Abstract][Full Text] [Related]
2. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.
Smith MR
Urology; 2004 Apr; 63(4):742-5. PubMed ID: 15072892
[TBL] [Abstract][Full Text] [Related]
3. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
[TBL] [Abstract][Full Text] [Related]
4. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.
Berruti A; Dogliotti L; Terrone C; Cerutti S; Isaia G; Tarabuzzi R; Reimondo G; Mari M; Ardissone P; De Luca S; Fasolis G; Fontana D; Rossetti SR; Angeli A;
J Urol; 2002 Jun; 167(6):2361-7; discussion 2367. PubMed ID: 11992038
[TBL] [Abstract][Full Text] [Related]
5. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men.
Leder BZ; Smith MR; Fallon MA; Lee ML; Finkelstein JS
J Clin Endocrinol Metab; 2001 Feb; 86(2):511-6. PubMed ID: 11158001
[TBL] [Abstract][Full Text] [Related]
6. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.
Smith MR; Lee H; McGovern F; Fallon MA; Goode M; Zietman AL; Finkelstein JS
Cancer; 2008 May; 112(10):2188-94. PubMed ID: 18348297
[TBL] [Abstract][Full Text] [Related]
7. [The role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: Results from the 'ELIRE' observational study].
Ouzaid I; Rouprêt M
Prog Urol; 2011 Nov; 21(12):866-74. PubMed ID: 22035913
[TBL] [Abstract][Full Text] [Related]
8. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
[TBL] [Abstract][Full Text] [Related]
9. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
[TBL] [Abstract][Full Text] [Related]
10. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition.
Smith MR; Goode M; Zietman AL; McGovern FJ; Lee H; Finkelstein JS
J Clin Oncol; 2004 Jul; 22(13):2546-53. PubMed ID: 15226323
[TBL] [Abstract][Full Text] [Related]
11. Insulin sensitivity during combined androgen blockade for prostate cancer.
Smith MR; Lee H; Nathan DM
J Clin Endocrinol Metab; 2006 Apr; 91(4):1305-8. PubMed ID: 16434464
[TBL] [Abstract][Full Text] [Related]
12. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
13. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.
Yannucci J; Manola J; Garnick MB; Bhat G; Bubley GJ
J Urol; 2006 Aug; 176(2):520-5. PubMed ID: 16813881
[TBL] [Abstract][Full Text] [Related]
14. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
[TBL] [Abstract][Full Text] [Related]
15. Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer.
Yu EY; Getzenberg RH; Coss CC; Gittelman MM; Keane T; Tutrone R; Belkoff L; Given R; Bass J; Chu F; Gambla M; Gaylis F; Bailen J; Hancock ML; Smith J; Dalton JT; Steiner MS
Eur Urol; 2015 Feb; 67(2):334-41. PubMed ID: 24968970
[TBL] [Abstract][Full Text] [Related]
16. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
17. Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?
Pickles T; Hamm J; Morris WJ; Schreiber WE; Tyldesley S
BJU Int; 2012 Dec; 110(11 Pt B):E500-7. PubMed ID: 22564197
[TBL] [Abstract][Full Text] [Related]
18. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer.
Smith MR; Lee H; Fallon MA; Nathan DM
Urology; 2008 Feb; 71(2):318-22. PubMed ID: 18308111
[TBL] [Abstract][Full Text] [Related]
19. Relationship between body mass index and serum testosterone concentration in patients receiving luteinizing hormone-releasing hormone agonist therapy for prostate cancer.
van der Sluis TM; van Moorselaar RJ; Meuleman EJ; ter Haar RW; Bui HN; Heijboer AC; Vis AN
Urology; 2013 May; 81(5):1005-9. PubMed ID: 23465153
[TBL] [Abstract][Full Text] [Related]
20. Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group.
Garnick MB; Campion M
Mol Urol; 2000; 4(3):275-7. PubMed ID: 11062384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]